Cv Sciences Financials
This page shows Cv Sciences (CVSI) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Cv Sciences has an operating margin of -3.4%, meaning the company retains $-3 of operating profit per $100 of revenue. This below-average margin results in a low score of 15/100, suggesting thin profitability after operating expenses. This is up from -13.9% the prior year.
Cv Sciences's revenue declined 12.2% year-over-year, from $15.7M to $13.8M. This contraction results in a growth score of 13/100.
Cv Sciences carries a low D/E ratio of 0.26, meaning only $0.26 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 97/100, indicating a strong balance sheet with room for future borrowing.
Cv Sciences's current ratio of 1.03 means current assets barely cover short-term liabilities. This tight liquidity results in a low score of 15/100, which could limit financial flexibility.
While Cv Sciences generated -$407K in operating cash flow, capex of $109K consumed most of it, leaving -$516K in free cash flow. This results in a low score of 16/100, reflecting heavy capital investment rather than weak cash generation.
Cv Sciences generates a -65.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -133.4% the prior year.
Cv Sciences passes 4 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Cv Sciences generates $0.42 in operating cash flow (-$407K OCF vs -$958K net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Cv Sciences earns $-0.9 in operating income for every $1 of interest expense (-$470K vs $517K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Cv Sciences generated $13.8M in revenue in fiscal year 2025. This represents a decrease of 12.2% from the prior year.
Cv Sciences's EBITDA was -$278K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 85.0% from the prior year.
Cv Sciences reported -$958K in net income in fiscal year 2025. This represents an increase of 60.0% from the prior year.
Cv Sciences earned $-0.01 per diluted share (EPS) in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Cash & Balance Sheet
Cv Sciences generated -$516K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 43.8% from the prior year.
Cv Sciences held $454K in cash against $387K in long-term debt as of fiscal year 2025.
Cv Sciences had 193M shares outstanding in fiscal year 2025. This represents an increase of 5.0% from the prior year.
Margins & Returns
Cv Sciences's gross margin was 49.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 3.3 percentage points from the prior year.
Cv Sciences's operating margin was -3.4% in fiscal year 2025, reflecting core business profitability. This is up 10.5 percentage points from the prior year.
Cv Sciences's net profit margin was -7.0% in fiscal year 2025, showing the share of revenue converted to profit. This is up 8.3 percentage points from the prior year.
Cv Sciences's ROE was -65.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 68.1 percentage points from the prior year.
Capital Allocation
Cv Sciences invested $122K in research and development in fiscal year 2025. This represents an increase of 3.4% from the prior year.
Cv Sciences invested $109K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 505.6% from the prior year.
CVSI Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.3M-10.1% | $3.6M+0.4% | $3.6M-7.2% | $3.9M+0.5% | $3.9M-2.3% | $4.0M-1.2% | $4.0M+5.3% | $3.8M |
| Cost of Revenue | $1.7M-5.6% | $1.8M-8.8% | $1.9M-11.7% | $2.2M+5.7% | $2.1M-0.3% | $2.1M-2.6% | $2.1M+4.4% | $2.1M |
| Gross Profit | $1.6M-14.4% | $1.8M+11.2% | $1.7M-1.1% | $1.7M-5.7% | $1.8M-4.4% | $1.9M+0.4% | $1.9M+6.4% | $1.7M |
| R&D Expenses | $24K-52.0% | $50K+66.7% | $30K+20.0% | $25K-13.8% | $29K+3.6% | $28K-22.2% | $36K-10.0% | $40K |
| SG&A Expenses | $1.8M-4.9% | $1.9M-10.0% | $2.1M-6.9% | $2.3M+10.0% | $2.1M-13.5% | $2.4M-0.9% | $2.4M-5.9% | $2.6M |
| Operating Income | -$275K-109.9% | -$131K-1290.9% | $11K+101.7% | -$646K-89.4% | -$341K+41.5% | -$583K+6.0% | -$620K+30.3% | -$889K |
| Interest Expense | $107K | N/A | N/A | N/A | $115K | N/A | N/A | N/A |
| Income Tax | $0 | $0-100.0% | $7K+150.0% | -$14K | $0 | $0-100.0% | $6K+166.7% | -$9K |
| Net Income | -$382K-46.4% | -$261K-139.4% | -$109K+85.0% | -$726K-59.2% | -$456K+21.9% | -$584K+7.0% | -$628K+27.7% | -$869K |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | N/A | $0.00 | $0.00 | $0.00 | N/A |
CVSI Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.0M-12.0% | $8.0M+2.4% | $7.8M-2.1% | $7.9M-5.5% | $8.4M-5.6% | $8.9M+5.0% | $8.5M-8.0% | $9.2M |
| Current Assets | $5.1M-14.2% | $5.9M-0.4% | $6.0M-4.5% | $6.2M-7.5% | $6.7M+0.2% | $6.7M-8.4% | $7.4M-7.4% | $7.9M |
| Cash & Equivalents | $381K-57.0% | $886K+9.1% | $812K+78.9% | $454K-53.6% | $979K+105.2% | $477K-27.9% | $662K-49.7% | $1.3M |
| Inventory | $4.1M-3.2% | $4.2M-3.5% | $4.4M-10.8% | $4.9M-2.5% | $5.0M-3.6% | $5.2M-9.6% | $5.8M+1.8% | $5.7M |
| Accounts Receivable | $405K-25.7% | $545K+26.7% | $430K-17.6% | $522K+23.7% | $422K-34.0% | $639K+26.0% | $507K+17.6% | $431K |
| Goodwill | $1.0M-0.3% | $1.0M+2.5% | $988K+1.8% | $971K+19.1% | $815K+11.8% | $729K+114.4% | $340K-0.6% | $342K |
| Total Liabilities | $5.5M-11.2% | $6.1M+4.7% | $5.9M-4.3% | $6.1M-1.1% | $6.2M-2.8% | $6.4M+4.5% | $6.1M-3.1% | $6.3M |
| Current Liabilities | $4.8M-16.1% | $5.7M+8.6% | $5.3M-14.0% | $6.1M-0.6% | $6.1M+1.9% | $6.0M+1.2% | $6.0M-2.6% | $6.1M |
| Long-Term Debt | $504K+142.3% | $208K-58.2% | $498K | $0 | N/A | N/A | N/A | N/A |
| Total Equity | $1.5M-14.6% | $1.8M-4.7% | $1.9M+5.4% | $1.8M-18.1% | $2.2M-12.6% | $2.5M+6.2% | $2.4M-18.6% | $2.9M |
| Retained Earnings | -$87.7M-0.4% | -$87.4M-0.3% | -$87.1M-0.1% | -$87.0M-0.8% | -$86.3M-0.5% | -$85.8M-0.7% | -$85.2M-0.7% | -$84.6M |
CVSI Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$259K-190.2% | $287K+454.3% | -$81K+60.1% | -$203K-66.4% | -$122K-114.0% | -$57K+89.0% | -$518K-354.4% | -$114K |
| Capital Expenditures | $11K-77.6% | $49K+22.5% | $40K+122.2% | $18K | $0 | $0 | $0 | N/A |
| Free Cash Flow | -$270K-213.4% | $238K+296.7% | -$121K+45.2% | -$221K-81.1% | -$122K-114.0% | -$57K+89.0% | -$518K | N/A |
| Investing Cash Flow | -$11K+77.6% | -$49K-22.5% | -$40K-81.8% | -$22K-164.7% | $34K+185.0% | -$40K | $0+100.0% | -$156K |
| Financing Cash Flow | -$234K-40.1% | -$167K-134.8% | $480K+243.3% | -$335K-156.8% | $590K+778.2% | -$87K+36.0% | -$136K-142.9% | -$56K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CVSI Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 48.5%-2.4pp | 50.9%+5.0pp | 46.0%+2.8pp | 43.2%-2.8pp | 46.0%-1.0pp | 47.0%+0.7pp | 46.3%+0.5pp | 45.8% |
| Operating Margin | -8.5%-4.8pp | -3.6%-3.9pp | 0.3%+16.9pp | -16.6%-7.8pp | -8.8%+5.9pp | -14.7%+0.8pp | -15.5%+7.9pp | -23.4% |
| Net Margin | -11.7%-4.5pp | -7.2%-4.2pp | -3.0%+15.7pp | -18.7%-6.9pp | -11.8%+3.0pp | -14.8%+0.9pp | -15.7%+7.2pp | -22.9% |
| Return on Equity | -24.8%-10.3pp | -14.5%-8.7pp | -5.8%+34.7pp | -40.5%-19.6pp | -20.8%+2.5pp | -23.3%+3.3pp | -26.6%+3.3pp | -29.9% |
| Return on Assets | -5.5%-2.2pp | -3.3%-1.9pp | -1.4%+7.8pp | -9.2%-3.7pp | -5.4%+1.1pp | -6.6%+0.9pp | -7.4%+2.0pp | -9.4% |
| Current Ratio | 1.06+0.0 | 1.04-0.1 | 1.14+0.1 | 1.02-0.1 | 1.10-0.0 | 1.12-0.1 | 1.23-0.1 | 1.30 |
| Debt-to-Equity | 0.33+0.2 | 0.12-0.1 | 0.26+0.3 | 0.00-2.8 | 2.83+0.3 | 2.54-0.0 | 2.58+0.4 | 2.17 |
| FCF Margin | -8.3%-14.9pp | 6.6%+9.9pp | -3.4%+2.3pp | -5.7%-2.5pp | -3.2%-1.7pp | -1.4%+11.5pp | -12.9% | N/A |
Similar Companies
Frequently Asked Questions
What is Cv Sciences's annual revenue?
Cv Sciences (CVSI) reported $13.8M in total revenue for fiscal year 2025. This represents a -12.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cv Sciences's revenue growing?
Cv Sciences (CVSI) revenue declined by 12.2% year-over-year, from $15.7M to $13.8M in fiscal year 2025.
Is Cv Sciences profitable?
No, Cv Sciences (CVSI) reported a net income of -$958K in fiscal year 2025, with a net profit margin of -7.0%.
What is Cv Sciences's EBITDA?
Cv Sciences (CVSI) had EBITDA of -$278K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Cv Sciences have?
As of fiscal year 2025, Cv Sciences (CVSI) had $454K in cash and equivalents against $387K in long-term debt.
What is Cv Sciences's gross margin?
Cv Sciences (CVSI) had a gross margin of 49.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Cv Sciences's operating margin?
Cv Sciences (CVSI) had an operating margin of -3.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Cv Sciences's net profit margin?
Cv Sciences (CVSI) had a net profit margin of -7.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cv Sciences's return on equity (ROE)?
Cv Sciences (CVSI) has a return on equity of -65.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cv Sciences's free cash flow?
Cv Sciences (CVSI) generated -$516K in free cash flow during fiscal year 2025. This represents a 43.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cv Sciences's operating cash flow?
Cv Sciences (CVSI) generated -$407K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Cv Sciences's total assets?
Cv Sciences (CVSI) had $7.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cv Sciences's capital expenditures?
Cv Sciences (CVSI) invested $109K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Cv Sciences spend on research and development?
Cv Sciences (CVSI) invested $122K in research and development during fiscal year 2025.
What is Cv Sciences's current ratio?
Cv Sciences (CVSI) had a current ratio of 1.03 as of fiscal year 2025, which is considered adequate.
What is Cv Sciences's debt-to-equity ratio?
Cv Sciences (CVSI) had a debt-to-equity ratio of 0.26 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cv Sciences's return on assets (ROA)?
Cv Sciences (CVSI) had a return on assets of -13.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cv Sciences's cash runway?
Based on fiscal year 2025 data, Cv Sciences (CVSI) had $454K in cash against an annual operating cash burn of $407K. This gives an estimated cash runway of approximately 13 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Cv Sciences's Piotroski F-Score?
Cv Sciences (CVSI) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cv Sciences's earnings high quality?
Cv Sciences (CVSI) has an earnings quality ratio of 0.42x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cv Sciences cover its interest payments?
Cv Sciences (CVSI) has an interest coverage ratio of -0.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Cv Sciences?
Cv Sciences (CVSI) scores 26 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.